港股異動 | 君實生物AH股逆勢上漲 阿達木單抗生物類似藥獲批上市 券商唱好
格隆匯3月4日丨君實生物(1877.HK)逆勢漲2.61%報54.95港元,君實生物A股午間收漲2.12%報78元。國家藥監局官網最新公示,君實生物提交的阿達木單抗生物類似藥(UBP1211)的上市申請已獲得批准。國盛證券點評稱,本次阿達木單抗獲批為後續業績增長再行奠基,公司商業化版圖實現了從腫瘤、抗感染領域向自身免疫病的歷史性跨越;極大地拓展了公司上市產品的覆蓋人羣,在擴充收入現金流的同時有助於完善公司銷售體系建設,進一步提升商業化影響力,助力實現覆蓋多種疾病領域的全面持續發展。維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.